Clinical Trials
4 trialsNCT04566393 2026-06-04
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05094336 2026-05-28
MTAPESTRY 101
Amgen
Phase 1/2 Active not recruiting
NCT06673329 2026-05-13
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Phase 1 Recruiting